Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MederaMDER Liabilities-to-Assets is 3.27 as of Jun. 2024.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Medera's Total Liabilities for the quarter that ended in Jun. 2024 was $10.11 Mil. Medera's Total Assets for the quarter that ended in Jun. 2024 was $3.09 Mil.
Therefore, Medera's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2024 was 3.27.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Medera Liabilities-to-Assets Related Terms
Medera Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Medera's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medera Liabilities-to-Assets Chart
Medera Annual Data
Trend
Dec22
Dec23
Liabilities-to-Assets
9.48
7.38
Medera Semi-Annual Data
Dec22
Jun23
Dec23
Jun24
Liabilities-to-Assets
9.48
0.00
7.38
3.27
MDER vs : Liabilities-to-Assets Comparison
For the Biotechnology subindustry, Medera's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medera Liabilities-to-Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medera's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Medera's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Medera's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medera (MDER) has a Liabilities-to-Assets of 3.27 as of Jun. 2024. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Medera and its competitors.
Is Medera's Liabilities-to-Assets too high?
Medera's current Liabilities-to-Assets is 3.27.
How does Medera's Liabilities-to-Assets compare to ?
Medera's Liabilities-to-Assets of 3.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Medera and its competitors. Medera's current Liabilities-to-Assets is 3.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medera stock overvalued right now?
Medera (MDER) has a current Liabilities-to-Assets of 3.27. The current Liabilities-to-Assets is 3.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Medera (MDER), the current Liabilities-to-Assets is 3.27 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medera Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics for difficult-to-treat and currently incurable diseases, with a focus on cardiovascular conditions. It operates through two business arms. Novoheart, its preclinical disease modeling and drug discovery brand, provides bioengineered human mini-heart technology and related platforms used for preclinical screening and drug discovery. Sardocor, its clinical development brand, advances novel gene therapies toward the clinic, leveraging the Novoheart platform to pursue an efficient regulatory path, particularly for cardiovascular diseases. The company's customers and collaborators include pharmaceutical and biotechnology companies, academic and research institutions, and other organizations that use its human heart modeling technologies for drug testing and development. Medera generates revenue primarily through research services, technology licensing, and collaboration arrangements, while its therapeutic candidates remain in preclinical and clinical development stages.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDER has been successfully added to your 
